<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03964480</url>
  </required_header>
  <id_info>
    <org_study_id>T-Cell Project 2.0</org_study_id>
    <nct_id>NCT03964480</nct_id>
  </id_info>
  <brief_title>Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.</brief_title>
  <official_title>Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Associazione Angela Serra per la ricerca sul cancro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Associazione Angela Serra per la ricerca sul cancro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study T-Cell Project 2.0 is based on the former International PTCL study designed by the
      International T-cell Non-Hodgkin's Lymphoma Study Group (T-Cell Project 1.0: Prospective
      Collection of Data in Patients With Peripheral T-Cell Lymphoma) as a prospective collection
      of data to predict the prognosis of patients with the more frequent subtypes of PTCL. It is a
      prospective, longitudinal, international, observational study of patients with newly
      diagnosed peripheral T-cell lymphoma aiming to verify whether this prospective collection of
      data would allow achieving a more accurate information on T-cell lymphomas.

      The study aims to better define the clinical relevance of the new WHO Classification, the
      role of FDG-PET in staging and response assessment, the prognosis of different entities, the
      genomic landscape of different subtypes, and to investigate on most optimal treatment
      strategies for these neoplasms in the real-world population as well as molecular markers and
      to explore the prognostic or predictive implications of them in PTCL.

      The study aims to better define the clinical relevance of the new WHO Classification, the
      role of FDG-PET in staging and response assessment, the prognosis of different entities, the
      genomic landscape of different subtypes, and to investigate on most optimal treatment
      strategies for these neoplasms in the real-world population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral T-cell non-Hodgkin lymphomas (PTCLs) are a heterogeneous group of
      lymphoproliferative disorder arising from mature T cells of post-thymic origin at different
      stages of differentiation with different morphological patterns, phenotypes, and clinical
      presentation. All subtypes are found more commonly in male patients, and the median age at
      diagnosis is 62 years. This disease is generally associated with high relapse rates and a
      poor prognosis, with inferior treatment outcomes compared with B-cell lymphomas and have a
      5-year-survival &lt; 32%.

      T-cell lymphomas are widely recognized as a complex and heterogeneous group of
      lymphoproliferative disorders, generally associated with high relapse rates and a poor
      prognosis. Because of their rarity, they are still very poorly understood.

      The introduction of new and more effective therapies and better technologies led the
      International T-cell non-Hodgkin's Lymphoma Study Group to launch the T-cell Project 2.0 in
      order to have a contemporary, real-time understanding of the T-cell lymphoma biology and
      treatment, together with the application of contemporary technologies to further
      identification of new therapeutic targets.

      Per protocol, patients are evaluated according to the treating physician's standard practice.
      There are no specific evaluations or visits required for the Registry. Data captured in the
      Registry reflects what is routinely collected for patients with PTCL.

      The study plans to collect the tissue sample for central review. The ordinary fixation,
      cryopreservation and routine tumor cytogenetics are planned for biopsy samples. Chairmen of
      the Histopathology Review Panel will locate Regional sites where expert hematopathologists
      will review the material and perform a panel of immunostains (T-cell panel + CD20) and
      markers not assessed at local site.

      Adding of blood sample collection will allow estimating prospectively the frequency of pEBVd
      detection in our cohort of PTCL patients at baseline and at the end of initial therapy, to
      characterize agreement between pEBVd and EBER in tumor tissue, and to explore the prognostic
      or predictive implications of detectable pEBVd in PTCL. Finally, to investigate the genetics
      and pathogenic mechanisms of aggressive PTCLs on an international scale.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>2 year</time_frame>
    <description>Measured from the date of diagnosis until the date of disease progression or death from T-cell Lymphoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3 and 5 year</time_frame>
    <description>Measured from the date of diagnosis until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>3 and 5 years</time_frame>
    <description>Measured from the date of diagnosis until the date of disease progression or death from T-cell Lymphoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>at 24 months</time_frame>
    <description>Measured from the date of diagnosis until the date of event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate (CR)</measure>
    <time_frame>at 30 months</time_frame>
    <description>Complete response rate at 30 months (CR30) after enrollment (i.e., initiation of treatment)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Peripheral T-Cell Lymphoma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Formalin-fixed tissue for central diagnostic pathology review; Peripheral blood samples.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Previously-untreated patients with de novo diagnosis of peripheral T-cell or NK/T-cell
        lymphoma:
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Previously-untreated patients with de novo diagnosis of peripheral T-cell or NK/T-cell
             lymphoma:

               -  T-cell large granular lymphocytic leukaemia;

               -  Chronic lymphoproliferative disorder of NK cells;

               -  Aggressive NK-cell leukaemia;

               -  Adult T-cell leukaemia/lymphoma;

               -  Extranodal NK/T-cell lymphoma, nasal type;

               -  Intestinal T-cell lymphoma;

               -  Hepatosplenic T-cell lymphoma;

               -  Subcutaneous panniculitis-like T-cell lymphoma;

               -  Peripheral T-cell lymphoma, not otherwise specified;

               -  Angioimmunoblastic T-cell lymphoma and other nodal lymphomas of T follicular
                  helper cell origin;

               -  Anaplastic large cell lymphoma, ALK-positive;

               -  Anaplastic large cell lymphoma, ALK-negative;

               -  Breast implant-associated anaplastic large cell lymphoma.

          2. Age 18 and over;

          3. Tissue biopsy adequate for diagnosis and classification and available for centralized
             review;

          4. Clinical data including baseline information on disease localization and laboratory
             parameters at staging, features of treatment adopted and assurance of follow-up
             updating for at least 2 years are requested;

          5. Written informed consent.

        Exclusion Criteria:

          1. Diagnosis of:

               -  EBV-positive T-cell and NK-cell lymphoproliferative diseases of childhood

               -  Mycosis fungoides;

               -  Sézary syndrome;

               -  Primary cutaneous CD30-positive T-cell lymphoproliferative disorders;

               -  Primary cutaneous peripheral T-cell lymphomas, rare subtypes;

               -  T-cell lymphoblastic lymphoma/leukemia

               -  T-cell prolymphocitic leukemia

          2. Age &lt; 18.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massimo Federico, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Modena and Reggio Emilia, Centro Oncologico Modenese, Modena, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Attilio Guarini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>U.O. Ematologia, IRCCS Istituto Tumori &quot;Giovanni Paolo II&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julie Vose, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Section of Hematology/Oncology, Nebraska Medical Center, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Horwitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miles Prince, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peter MacCallum Cancer Center, Melbourne, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kim Won Seog, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematology-Oncology Samsung Medical Center, Seoul, South Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dolores Caballero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Biosanitaria de Salamanca, Salamanca, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Zaya, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Sanitaria Universitaria Integrata S.M. Misericordia, Udine, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefano Luminari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>S.C. Ematologia, Arcispedale S. Maria Nuova-IRCCS, Reggio Emilia, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ranjana Advani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University Medical Center, Stanford, CA, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrei Shustov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Cancer Care Alliance, Seattle, WA, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierluigi Porcu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematopoietic Stem Cell Transplantation, Sidney Kimmel Cancer Center, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Astrid Pavlovsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Hematologia, FUNDALEU, Buenos Aires, Argentina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Chiattone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Departamento de Clinica Médica, FCM da Santa Casa de Sao Paulo, Sao Paulo, Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francine Foss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University School of Medicine, New Haven, CT, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Fox, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martina Manni, MSc, PhD</last_name>
    <phone>+390594223284</phone>
    <email>marmanni@unimore.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monica Civallero, MSc, PhD</last_name>
    <phone>+390594223475</phone>
    <email>monica.civallero@unimore.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ranjana Advani, MD</last_name>
      <phone>650-725-6456</phone>
      <email>radvani@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Catherine Lam, MSc, PhD</last_name>
      <phone>+16507230437</phone>
      <email>jclam11@stanford.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Tumori &quot;Giovanni Paolo II&quot;</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Attilio Guarini, MD</last_name>
      <phone>0039080/5555 905</phone>
      <email>attilioguarini@oncologico.bari.it</email>
    </contact>
    <contact_backup>
      <last_name>Angela Monica Sciacovelli, PhD</last_name>
      <phone>0039080/5555 416</phone>
      <email>angelamonicasciacovelli@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Palermo_La Maddalena</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maurizio Musso, MD</last_name>
      <phone>00 39 091-688 6801</phone>
      <email>mamusso53@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Emilio Ianitto, MD</last_name>
      <phone>00 39 091-680 6603</phone>
      <email>emilio.iannitto@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Terni-Santa Maria</name>
      <address>
        <city>Terni</city>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Marina Liberati, MD</last_name>
      <phone>00390744205971</phone>
      <email>marina.liberati@unipg.it</email>
    </contact>
    <contact_backup>
      <last_name>Viviana Appolloni, PhD</last_name>
      <phone>00390744205971</phone>
      <email>appolloniviviana@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cluj Napoca_Ion Chiricuta Oncology Institute</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciprian Tomuleasa, MD</last_name>
      <phone>0040741337480</phone>
      <email>ciprian.tomuleasa@umfcluj.ro</email>
    </contact>
    <contact_backup>
      <last_name>Catalin Vlad, MD</last_name>
      <phone>0040264598362</phone>
      <email>catalinvlad@yahoo.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Kiev</city>
        <zip>03022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iryna Kriachok, MD</last_name>
      <phone>+380442572156</phone>
      <email>irina.kryachok@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Tetiana Skrypets, MD</last_name>
      <phone>+380502526606</phone>
      <email>skrip@ua.fm</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Romania</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bloodjournal.org/content/130/Suppl_1/4072</url>
    <description>Shustov AR, Bellei M, et al.: Clinical Outcomes of Patients with Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase-Positive (ALCL, ALK+): Data from 119 Patients Prospectively Registered in the International T-Cell Project. Blood 130:4072, 2017</description>
  </link>
  <link>
    <url>http://www.bloodjournal.org/content/130/Suppl_1/4071</url>
    <description>Shustov AR, Cabrera ME, Bellei M, et al: Clinical Outcomes of Patients with Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase-Negative (ALCL, ALK-): Analysis of 203 Patients Prospectively Registered in the International T-Cell Project.</description>
  </link>
  <link>
    <url>http://www.bloodjournal.org/content/130/Suppl_1/1512</url>
    <description>Foss F, Horwitz S, Bellei M, et al: Outcome of Patients with Gamma Delta T Cell Lymphomas: Analysis of 1429 Cases Registered in the Prospective T-Cell Project. Blood 130:1512, 2017</description>
  </link>
  <link>
    <url>http://www.bloodjournal.org/content/128/22/921</url>
    <description>Bellei M, Foss F, Horwitz S, et al: The Outcome of Patients with Primary Refractory or Relapsed Peripheral T-Cell Lymphoma: Analysis of 1020 Cases Registered in the Prospective T-Cell Project. Blood 128:921, 2016</description>
  </link>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/10.1002/hon.2059</url>
    <description>Pileri S, Federico M, Fossa F, et al: Pooled analysis of biomarker data quality from the Tcell project and complete studies. Hematol Oncol 31 (Suppl.:201-270, 2013</description>
  </link>
  <link>
    <url>http://onlinelibrary.wiley.com/toc/10991069/2017/35/S2</url>
    <description>Fox C, Bellei M, Manni M, et al: Improved survival outcomes for patients with extra‐nodal nk/t lymphoma: data from 140 patients prospectively registered in the international T-cell project. Hematol Oncol 35:1-466, 2017</description>
  </link>
  <reference>
    <citation>Ansell S. How to select the frontline treatment for a patient with peripheral T-cell lymphoma. Leuk Lymphoma. 2016;57(4):783-8. doi: 10.3109/10428194.2016.1140760. Epub 2016 Feb 5. Review.</citation>
    <PMID>26850659</PMID>
  </reference>
  <reference>
    <citation>Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008 Sep 1;26(25):4124-30. doi: 10.1200/JCO.2008.16.4558. Epub 2008 Jul 14.</citation>
    <PMID>18626005</PMID>
  </reference>
  <reference>
    <citation>A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997 Jun 1;89(11):3909-18.</citation>
    <PMID>9166827</PMID>
  </reference>
  <reference>
    <citation>Savage KJ. Peripheral T-cell lymphomas. Blood Rev. 2007 Jul;21(4):201-16. Epub 2007 May 18. Review.</citation>
    <PMID>17512649</PMID>
  </reference>
  <reference>
    <citation>Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, Greiner TC, Smith L, Guo S, Wilcox RA, Teh BT, Lim ST, Tan SY, Rimsza LM, Jaffe ES, Campo E, Martinez A, Delabie J, Braziel RM, Cook JR, Tubbs RR, Ott G, Geissinger E, Gaulard P, Piccaluga PP, Pileri SA, Au WY, Nakamura S, Seto M, Berger F, de Leval L, Connors JM, Armitage J, Vose J, Chan WC, Staudt LM; Lymphoma Leukemia Molecular Profiling Project and the International Peripheral T-cell Lymphoma Project. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014 May 8;123(19):2915-23. doi: 10.1182/blood-2013-11-536359. Epub 2014 Mar 14.</citation>
    <PMID>24632715</PMID>
  </reference>
  <reference>
    <citation>Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018 Feb 9;8(2):15. doi: 10.1038/s41408-018-0054-y. Review.</citation>
    <PMID>29426921</PMID>
  </reference>
  <reference>
    <citation>Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood. 2011 Jun 23;117(25):6756-67. doi: 10.1182/blood-2010-05-231548. Epub 2011 Apr 14. Review.</citation>
    <PMID>21493798</PMID>
  </reference>
  <reference>
    <citation>Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, Rüdiger T, Pileri S, Nakamura S, Nathwani B, Campo E, Berger F, Coiffier B, Kim WS, Holte H, Federico M, Au WY, Tobinai K, Armitage JO, Vose JM; International Peripheral T-cell Lymphoma Project. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011 Mar 24;117(12):3402-8. doi: 10.1182/blood-2010-09-310342. Epub 2011 Jan 26.</citation>
    <PMID>21270441</PMID>
  </reference>
  <reference>
    <citation>Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, Morabito F, Martelli M, Brusamolino E, Iannitto E, Zaja F, Cortelazzo S, Rigacci L, Devizzi L, Todeschini G, Santini G, Brugiatelli M, Federico M; Intergruppo Italiano Linfomi. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004 Apr 1;103(7):2474-9. Epub 2003 Nov 26.</citation>
    <PMID>14645001</PMID>
  </reference>
  <reference>
    <citation>Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, Bacci F, Falini B, Motta T, Paulli M, Artusi T, Piccioli M, Zinzani PL, Pileri SA. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006 Jun 1;24(16):2472-9. Epub 2006 Apr 24.</citation>
    <PMID>16636342</PMID>
  </reference>
  <reference>
    <citation>Lage LA, Cabral TC, Costa Rde O, Gonçalves Mde C, Levy D, Zerbini MC, Pereira J. Primary nodal peripheral T-cell lymphomas: diagnosis and therapeutic considerations. Rev Bras Hematol Hemoter. 2015 Jul-Aug;37(4):277-84. doi: 10.1016/j.bjhh.2015.03.017. Epub 2015 Jun 7.</citation>
    <PMID>26190436</PMID>
  </reference>
  <reference>
    <citation>Dearden CE, Johnson R, Pettengell R, Devereux S, Cwynarski K, Whittaker S, McMillan A; British Committee for Standards in Haematology. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol. 2011 May;153(4):451-85. doi: 10.1111/j.1365-2141.2011.08651.x. Epub 2011 Apr 11. Review.</citation>
    <PMID>21480860</PMID>
  </reference>
  <reference>
    <citation>Karakas T, Bergmann L, Stutte HJ, Jäger E, Knuth A, Weidmann E, Mitrou PS, Hoelzer D. Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas. Leuk Lymphoma. 1996 Dec;24(1-2):121-9.</citation>
    <PMID>9049968</PMID>
  </reference>
  <reference>
    <citation>Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, Peter N, Loeffler M, Rosenwald A, Pfreundschuh M. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010 Nov 4;116(18):3418-25. doi: 10.1182/blood-2010-02-270785. Epub 2010 Jul 21.</citation>
    <PMID>20660290</PMID>
  </reference>
  <reference>
    <citation>d'Amore F, Gaulard P, Trümper L, Corradini P, Kim WS, Specht L, Bjerregaard Pedersen M, Ladetto M; ESMO Guidelines Committee. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26 Suppl 5:v108-15. doi: 10.1093/annonc/mdv201.</citation>
    <PMID>26314772</PMID>
  </reference>
  <reference>
    <citation>Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, Kluin-Nelemans JC, Ladetto M, Le Gouill S, Iannitto E, Pileri S, Rodriguez J, Schmitz N, Wotherspoon A, Zinzani P, Zucca E. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013 Apr;24(4):857-77. doi: 10.1093/annonc/mds643. Epub 2013 Feb 20.</citation>
    <PMID>23425945</PMID>
  </reference>
  <reference>
    <citation>Reddy NM, Evens AM. Chemotherapeutic advancements in peripheral T-cell lymphoma. Semin Hematol. 2014 Jan;51(1):17-24. doi: 10.1053/j.seminhematol.2013.11.006. Epub 2013 Nov 14. Review.</citation>
    <PMID>24468312</PMID>
  </reference>
  <reference>
    <citation>Cheah CY, Oki Y, Fanale MA. Novel treatments for T-cell lymphoma. Am Soc Clin Oncol Educ Book. 2015:e468-78. doi: 10.14694/EdBook_AM.2015.35.e468. Review.</citation>
    <PMID>25993211</PMID>
  </reference>
  <reference>
    <citation>Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald AP, Repp R, Schetelig J, Seipelt G, Osterborg A. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004 Apr 15;103(8):2920-4. Epub 2003 Dec 30.</citation>
    <PMID>15070664</PMID>
  </reference>
  <reference>
    <citation>Zinzani PL, Alinari L, Tani M, Fina M, Pileri S, Baccarani M. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica. 2005 May;90(5):702-3.</citation>
    <PMID>15921394</PMID>
  </reference>
  <reference>
    <citation>Zinzani PL, Venturini F, Stefoni V, Fina M, Pellegrini C, Derenzini E, Gandolfi L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccarani M. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol. 2010 Apr;21(4):860-863. doi: 10.1093/annonc/mdp508. Epub 2009 Nov 3.</citation>
    <PMID>19887465</PMID>
  </reference>
  <reference>
    <citation>Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M, Pellegrini C, Alinari L, Derenzini E, de Vivo A, Sabattini E, Pileri S, Baccarani M. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007 Sep 20;25(27):4293-7. Epub 2007 Aug 20.</citation>
    <PMID>17709797</PMID>
  </reference>
  <reference>
    <citation>Toumishey E, Prasad A, Dueck G, Chua N, Finch D, Johnston J, van der Jagt R, Stewart D, White D, Belch A, Reiman T. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer. 2015 Mar 1;121(5):716-23. doi: 10.1002/cncr.29103. Epub 2014 Oct 29.</citation>
    <PMID>25355245</PMID>
  </reference>
  <reference>
    <citation>Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, Glaisner S, Gabarre J, Bosly A, Lister J, Li J, Coiffier B. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer. 2013 Sep;49(13):2869-76. doi: 10.1016/j.ejca.2013.04.029. Epub 2013 May 31.</citation>
    <PMID>23731832</PMID>
  </reference>
  <reference>
    <citation>O'Connor OA, Horwitz S, Hamlin P, Portlock C, Moskowitz CH, Sarasohn D, Neylon E, Mastrella J, Hamelers R, Macgregor-Cortelli B, Patterson M, Seshan VE, Sirotnak F, Fleisher M, Mould DR, Saunders M, Zelenetz AD. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol. 2009 Sep 10;27(26):4357-64. doi: 10.1200/JCO.2008.20.8470. Epub 2009 Aug 3.</citation>
    <PMID>19652067</PMID>
  </reference>
  <reference>
    <citation>O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011 Mar 20;29(9):1182-9. doi: 10.1200/JCO.2010.29.9024. Epub 2011 Jan 18.</citation>
    <PMID>21245435</PMID>
  </reference>
  <reference>
    <citation>Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, Banos A, Jaccard A, Park S, Tournilhac O, Schiano-de Collela JM, Voillat L, Joly B, Le Gouill S, Saad A, Cony-Makhoul P, Vilque JP, Sanhes L, Schmidt-Tanguy A, Bubenheim M, Houot R, Diouf M, Marolleau JP, Béné MC, Martin A, Lamy T. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013 Jan 1;31(1):104-10. doi: 10.1200/JCO.2012.43.7285. Epub 2012 Oct 29.</citation>
    <PMID>23109692</PMID>
  </reference>
  <reference>
    <citation>Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ, Figg WD, Steinberg SM, Smith S, Joske D, Lewis I, Hutchins L, Craig M, Fojo AT, Wright JJ, Bates SE. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011 Jun 2;117(22):5827-34. doi: 10.1182/blood-2010-10-312603. Epub 2011 Feb 25.</citation>
    <PMID>21355097</PMID>
  </reference>
  <reference>
    <citation>Suwiwat S, Pradutkanchana J, Ishida T, Mitarnun W. Quantitative analysis of cell-free Epstein-Barr virus DNA in the plasma of patients with peripheral T-cell and NK-cell lymphomas and peripheral T-cell proliferative diseases. J Clin Virol. 2007 Dec;40(4):277-83. Epub 2007 Nov 9.</citation>
    <PMID>17996493</PMID>
  </reference>
  <reference>
    <citation>Kim YR, Kim SJ, Cheong JW, Chung H, Jang JE, Kim Y, Yang WI, Min YH, Kim JS. Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma. Oncotarget. 2017 Sep 23;8(54):92312-92323. doi: 10.18632/oncotarget.21251. eCollection 2017 Nov 3.</citation>
    <PMID>29190917</PMID>
  </reference>
  <reference>
    <citation>Lynch RC, Gratzinger D, Advani RH. Clinical Impact of the 2016 Update to the WHO Lymphoma Classification. Curr Treat Options Oncol. 2017 Jul;18(7):45. doi: 10.1007/s11864-017-0483-z. Review. Erratum in: Curr Treat Options Oncol. 2017 Oct;18(10 ):60.</citation>
    <PMID>28670664</PMID>
  </reference>
  <reference>
    <citation>Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Sep 20;32(27):3059-68.</citation>
    <PMID>25113753</PMID>
  </reference>
  <reference>
    <citation>Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007 Mar 15;165(6):710-8. Epub 2006 Dec 20.</citation>
    <PMID>17182981</PMID>
  </reference>
  <reference>
    <citation>Ogundimu EO, Altman DG, Collins GS. Adequate sample size for developing prediction models is not simply related to events per variable. J Clin Epidemiol. 2016 Aug;76:175-82. doi: 10.1016/j.jclinepi.2016.02.031. Epub 2016 Mar 8.</citation>
    <PMID>26964707</PMID>
  </reference>
  <reference>
    <citation>Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996 Feb 28;15(4):361-87. Review.</citation>
    <PMID>8668867</PMID>
  </reference>
  <reference>
    <citation>Royston P, Sauerbrei W. A new measure of prognostic separation in survival data. Stat Med. 2004 Mar 15;23(5):723-48.</citation>
    <PMID>14981672</PMID>
  </reference>
  <reference>
    <citation>Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55.</citation>
    <PMID>7165009</PMID>
  </reference>
  <reference>
    <citation>Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012 Feb 20;30(6):631-6. doi: 10.1200/JCO.2011.37.4223. Epub 2012 Jan 23.</citation>
    <PMID>22271479</PMID>
  </reference>
  <reference>
    <citation>Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan Iyer S, Shustov A, Nielsen T, Nichols J, Wolfson J, Balser B, Horwitz S. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014 Jan 23;7:11. doi: 10.1186/1756-8722-7-11.</citation>
    <PMID>24456586</PMID>
  </reference>
  <reference>
    <citation>Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012 Jun 20;30(18):2190-6. doi: 10.1200/JCO.2011.38.0402. Epub 2012 May 21.</citation>
    <PMID>22614995</PMID>
  </reference>
  <reference>
    <citation>Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O'Connor OA, Siddiqi T, Kennedy DA, Oki Y. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014 May 15;123(20):3095-100. doi: 10.1182/blood-2013-12-542142. Epub 2014 Mar 20.</citation>
    <PMID>24652992</PMID>
  </reference>
  <reference>
    <citation>Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben-Yehuda D, Beylot-Barry M, Hillen U, Knoblauch P, Bhat G, Chawla S, Allen LF, Pohlman B. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015 Mar;168(6):811-9. doi: 10.1111/bjh.13222. Epub 2014 Nov 17.</citation>
    <PMID>25404094</PMID>
  </reference>
  <reference>
    <citation>O'Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, Hess G, Jurczak W, Knoblauch P, Chawla S, Bhat G, Choi MR, Walewski J, Savage K, Foss F, Allen LF, Shustov A. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. J Clin Oncol. 2015 Aug 10;33(23):2492-9. doi: 10.1200/JCO.2014.59.2782. Epub 2015 Jun 22.</citation>
    <PMID>26101246</PMID>
  </reference>
  <reference>
    <citation>Bellei M, Sabattini E, Pesce EA, Ko YH, Kim WS, Cabrera ME, Martinez V, Dlouhy I, Paes RP, Barrese T, Vassallo J, Tarantino V, Vose J, Weisenburger D, Rüdiger T, Federico M, Pileri S. Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-Cell Project, an international, cooperative study. Hematol Oncol. 2017 Dec;35(4):630-636. doi: 10.1002/hon.2316. Epub 2016 Jun 3.</citation>
    <PMID>27255982</PMID>
  </reference>
  <reference>
    <citation>Boddicker RL, Razidlo GL, Feldman AL. Genetic alterations affecting GTPases and T-cell receptor signaling in peripheral T-cell lymphomas. Small GTPases. 2019 Jan;10(1):33-39. doi: 10.1080/21541248.2016.1263718. Epub 2017 Jan 6. Review.</citation>
    <PMID>27898263</PMID>
  </reference>
  <reference>
    <citation>Haverkos BM, Huang Y, Gru A, Pancholi P, Freud AG, Mishra A, Ruppert AS, Baiocchi RA, Porcu P. Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas. Int J Cancer. 2017 Apr 15;140(8):1899-1906. doi: 10.1002/ijc.30566.</citation>
    <PMID>27943278</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>May 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2019</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral T-Cell Lymphoma</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Outcome</keyword>
  <keyword>Biological Characteristics</keyword>
  <keyword>Heterogeneity</keyword>
  <keyword>Rare Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We plan to share with other involved researchers the minimum information on IPD for publication.</ipd_description>
    <ipd_time_frame>Preliminary analysis results will be made available during the study on the single population and separately for each sub-type. Final results will be made available 6-12 months after the end of the study.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

